Cite
HARVARD Citation
Yamamoto, T. et al. (2019). A unique nanoparticulate TLR9 agonist enables a HA split vaccine to confer FcγR-mediated protection against heterologous lethal influenza virus infection. International immunology. pp. 81-90. [Online].